Media ReleasesArovella Therapeutics

View All Arovella Therapeutics News


SUDA Pharmaceuticals Product Development Market Update



Key points:

  • 505(b)(2) abbreviated pathway requires significantly less time and lower investments in direct research and development expenditures
  • SUDA prioritising its internal development efforts on 2 projects
  • Successful co-development strategy
  • Co-development projects de-risks the company and are non-balance sheet dilutive.
  • Number of deals that SUDA has transacted on totals 11.

For more information, download the attached PDF.

  Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?